Market Place
Sourcing Support
All News #Library
Biotech
Abeona Adds New ZEVASKYN Qualified Treatment Center in NY
02 Apr 2026 //
GLOBENEWSWIRE
ZEVASKYN Gene Therapy Now Offered in Francisco Treatment Center
15 Jul 2025 //
GLOBENEWSWIRE
Beacon Exercises Option for AAV204 Gene Therapy Capsid
01 Jul 2025 //
GLOBENEWSWIRE
Abeona Therapeutics Reports Q1 2025 Financial Results and Updates
15 May 2025 //
GLOBENEWSWIRE
Abeona, Lurie Open Zevaskyn Gene Therapy Center for Skin Wounds
14 May 2025 //
GLOBENEWSWIRE
Abeona, Lurie Children’s Launch ZEVASKYN™ Gene Therapy Center
14 May 2025 //
GLOBENEWSWIRE
Abeona Therapeutics® Sells Priority Review Voucher for $155M
12 May 2025 //
GLOBENEWSWIRE
Abeona Therapeutics to Present at Leerink Partners Conference
04 Mar 2025 //
GLOBENEWSWIRE
Abeona Completes Pz-cel Biologics License Resubmission to FDA
29 Oct 2024 //
GLOBENEWSWIRE
Abeona Announces New Employee Inducement Grants Under Nasdaq Listing Rule
02 Sep 2024 //
GLOBENEWSWIRE
Abeona Therapeutics Announces Favorable Medicare Decisions For Pz-cel
13 Aug 2024 //
GLOBENEWSWIRE
Abeona Therapeutics Reports Q1 2024 Financials, Corporate Progress
15 May 2024 //
GLOBENEWSWIRE
Abeona Therapeutics Provides Regulatory Update on Pz-cel
22 Apr 2024 //
GLOBENEWSWIRE
Abeona Announces Progress Update on Pz-cel Biologics License Application (BLA)
01 Feb 2024 //
GLOBENEWSWIRE
Abeona Announces FDA Accepts and Grants Priority Review for Pz-cel BLA
27 Nov 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Submits BLA to U.S. FDA Seeking Priority Review of EB-101
26 Sep 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101
30 Aug 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Abeona Announces Submission of Briefing Package for BLA Meeting with FDA
28 Jul 2023 //
GLOBENEWSWIRE
FDA wants more data from Abeona Therapeutics as it pushes for BLA
10 Jun 2023 //
ENDPTS
Abeona Therapeutics Announces Regulatory Update on BLA for EB-101
09 Jun 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Announces New Data from its AAV Ophthalmology Program
16 May 2023 //
GLOBENEWSWIRE
Abeona Announces Additional Phase 3 VIITAL Study Results for EB-101 Presented
11 May 2023 //
GLOBENEWSWIRE
Abeona Therapeutics Reports First Quarter 2023 Financial Results
11 May 2023 //
GLOBENEWSWIRE
Abeona Announces Multiple Abstracts Accepted from its AAV Ophthalmology Program
10 Apr 2023 //
GLOBENEWSWIRE
Abeona Announces Acceptance of Abstract on EB-101 Phase 3 VIITAL Study Results
16 Mar 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.